Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Volker Moebus

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Breast Care (Basel, Switzerland)|January 14, 2014
Is symptom-oriented follow-up still up to date?Christoph Mundhenke, Volker Moebus
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 19, 2010
Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33)Sibylle Loibl, Volkmar Mueller, Gunter von Minckwitz, et al.
Acta Oncologica (Stockholm, Sweden)|October 5, 2019
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancerAntroula Papakonstantinou, Elham Hedayati, Mats Hellström, et al.
Journal of the National Cancer Institute|July 18, 2013
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trialVolker Moebus, Christian Jackisch, Andreas Schneeweiss, et al.
Journal of the National Cancer Institute|March 4, 2014
ResponseVolker Moebus, Christian Jackisch, Andreas Schneeweiss, et al.
Cancer|December 19, 2019
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trialAntroula Papakonstantinou, Alexios Matikas, Nils Olof Bengtsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III studyVolker Moebus, Christian Jackisch, Hans-Joachim Lueck, et al.
ESMO Open|November 6, 2020
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trialMatteo Lambertini, Dominique Agbor-Tarh, Otto Metzger-Filho, et al.
Lancet (London, England)|May 5, 2009
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trialsJulia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
The Cochrane Database of Systematic Reviews|July 10, 2009
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient dataJulia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Breast Care (Basel, Switzerland)|January 14, 2014
Is symptom-oriented follow-up still up to date?Christoph Mundhenke, Volker Moebus
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 19, 2010
Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33)Sibylle Loibl, Volkmar Mueller, Gunter von Minckwitz, et al.
Acta Oncologica (Stockholm, Sweden)|October 5, 2019
Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancerAntroula Papakonstantinou, Elham Hedayati, Mats Hellström, et al.
Journal of the National Cancer Institute|July 18, 2013
Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: randomized clinical trialVolker Moebus, Christian Jackisch, Andreas Schneeweiss, et al.
Journal of the National Cancer Institute|March 4, 2014
ResponseVolker Moebus, Christian Jackisch, Andreas Schneeweiss, et al.
Cancer|December 19, 2019
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trialAntroula Papakonstantinou, Alexios Matikas, Nils Olof Bengtsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III studyVolker Moebus, Christian Jackisch, Hans-Joachim Lueck, et al.
ESMO Open|November 6, 2020
Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trialMatteo Lambertini, Dominique Agbor-Tarh, Otto Metzger-Filho, et al.
Lancet (London, England)|May 5, 2009
Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trialsJulia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
The Cochrane Database of Systematic Reviews|July 10, 2009
Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient dataJulia Bohlius, Kurt Schmidlin, Corinne Brillant, et al.
Pageof 2